Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agile Therapeutics, Inc. - Common Stock (NQ:AGRX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Agile Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Delisting from Nasdaq
From Agile Therapeutics, Inc.
Via GlobeNewswire
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
Live Conference Call and Webcast at 8:30 a.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
Live Conference Call and Webcast at 8:30 a.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
Elimination of Remaining Debt to Perceptive Advisors Leaves the Company’s Balance Sheet Debt Free 
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
Via ACCESSWIRE
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group
Via ACCESSWIRE
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
Via ACCESSWIRE
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
Live Conference Call and Webcast at 8:30 a.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys
Via ACCESSWIRE
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
Via ACCESSWIRE
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden’s Latest Executive Order Expanding Contraceptive Coverage
Via ACCESSWIRE
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
Via ACCESSWIRE
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
Via ACCESSWIRE
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?
Via ACCESSWIRE
The Overturning of Roe v. Wade Has Changed the Landscape of Birth Control; Smaller Companies are now an Integral Part of Care
Via ACCESSWIRE
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
From Agile Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS